7,080 Shares in DexCom, Inc. $DXCM Acquired by Nwam LLC

Nwam LLC acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 7,080 shares of the medical device company’s stock, valued at approximately $445,000.

Several other large investors have also recently added to or reduced their stakes in DXCM. Reflection Asset Management purchased a new stake in DexCom in the 4th quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom during the 1st quarter valued at $25,000. CVA Family Office LLC increased its stake in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares during the last quarter. MCF Advisors LLC acquired a new position in shares of DexCom in the fourth quarter worth $32,000. Finally, ORG Partners LLC raised its holdings in shares of DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on DXCM. Raymond James Financial restated a “strong-buy” rating and issued a $91.00 target price on shares of DexCom in a research note on Monday, June 8th. Benchmark reiterated a “buy” rating on shares of DexCom in a report on Tuesday, June 23rd. Mizuho increased their price objective on DexCom from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday. Robert W. Baird set a $80.00 price objective on shares of DexCom in a research report on Friday, May 1st. Finally, Bank of America reduced their target price on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.36.

Insider Activity

In other news, insider Kevin R. Sayer sold 26,756 shares of the company’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $72.00, for a total transaction of $1,926,432.00. Following the completion of the transaction, the insider directly owned 355,726 shares in the company, valued at $25,612,272. The trade was a 7.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.55, for a total value of $128,435.00. Following the completion of the sale, the executive vice president directly owned 106,353 shares of the company’s stock, valued at $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,750 shares of company stock worth $5,163,241 over the last 90 days. Company insiders own 0.28% of the company’s stock.

DexCom Price Performance

NASDAQ DXCM opened at $76.65 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The company has a fifty day simple moving average of $71.16 and a 200 day simple moving average of $68.73. The company has a market cap of $29.58 billion, a P/E ratio of 32.76, a P/E/G ratio of 1.28 and a beta of 1.45. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The firm’s revenue was up 15.0% compared to the same quarter last year. During the same period last year, the business posted $0.32 earnings per share. On average, sell-side analysts predict that DexCom, Inc. will post 2.57 EPS for the current year.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.